BioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020

Rhea-AI Summary

BioNTech (BNTX) will announce its Q2 2020 financial results on August 11, 2020, followed by a conference call at 08:00 a.m. EDT. Investors can access a webcast of the event and see a slide presentation. The company focuses on immunotherapy, developing innovative treatments for cancer and infectious diseases using mRNA technology. BioNTech collaborates with several major pharmaceutical companies, including Pfizer and Sanofi, to advance its diverse pipeline of therapies and vaccines.

Positive

• Collaboration with multiple global pharmaceutical partners enhances R&D capabilities.
• Focus on mRNA technology positions BioNTech at the forefront of vaccine development.

Negative

• None.

MAINZ, Germany, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2020 on Tuesday, August 11^th, 2020. BioNTech will also host a conference call and webcast on the same day at 08:00 a.m. EDT (2:00 p.m. CEST) to report its financial results and provide a corporate update on the second quarter 2020.

The slide presentation and audio of the webcast will be available via the following link: https://edge.media-server.com/mmc/p/45bam4wq

To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:

United States international:	+1 646 741 3167
United States domestic (toll-free):	+1 877 870 9135
Germany:	+49 (0) 692 2222 625
Conference ID:	1963889

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.de/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit www.BioNTech.de.

BioNTech Contacts:

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513 or +49 (0)151 1978 1385
Media@biontech.de

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de

FAQ

When will BioNTech announce its Q2 2020 financial results?

BioNTech will announce its Q2 2020 financial results on August 11, 2020.

What time is the BioNTech Q2 2020 conference call?

The BioNTech Q2 2020 conference call will take place at 08:00 a.m. EDT on August 11, 2020.

How can I access BioNTech's Q2 2020 financial results webcast?

You can access the Q2 2020 financial results webcast via BioNTech's Investor Relations website.

What industry is BioNTech involved in?

BioNTech is involved in biopharmaceuticals, focusing on immunotherapy and mRNA vaccine development.

Who are BioNTech's collaborators?

BioNTech collaborates with major pharmaceutical companies including Pfizer, Sanofi, and Genmab.